Cibus, INC 8-K filings

Cibus Inc. has appointed Cornelis Broos as Interim Chief Financial Officer, effective immediately, following the departure of Wade King.

Cibus Inc. has partially exercised an underwriter option, resulting in the sale of 289,953 additional shares of Class A common stock at $4.00 per share.

Cibus, Inc. has entered into an underwriting agreement for a public offering of 3,000,000 shares of its Class A common stock at $4.00 per share, expected to close on September 19, 2024.

Cibus, a gene editing agricultural biotech company, updated its business strategy, focusing on launching three key traits and advancing its technology platform.

Cibus Inc. has announced that its Chief Financial Officer, Wade King, will take an indefinite leave of absence, effective September 30, 2024, and will be replaced by Carlo Broos as Interim CFO.

Cibus announced its second quarter financial results, highlighting progress in commercial agreements, trait development, and regulatory approvals for its gene editing technologies.

Cibus Inc. has entered into agreements to sell shares and warrants for approximately $13 million in a registered direct offering.

Cibus Inc. successfully held its 2024 Annual Meeting, electing six directors, approving executive compensation, and ratifying the appointment of BDO USA, P.C. as its auditor.

Cibus announced its first quarter 2024 financial results, highlighting commercial progress with its gene editing platform and advancements in regulatory approvals.

Cibus Inc. has released unaudited pro forma combined financial statements for the year ended December 31, 2023, following its merger with Cibus Global, LLC.

Cibus, Inc. announced its full year 2023 financial results and provided a business update, highlighting commercial advancements in its gene editing technology and collaborations with major seed companies.

Cibus Inc. reports a preliminary non-cash impairment charge of approximately $249.4 million related to goodwill and in-process R&D intangible assets for the year ended December 31, 2023.